Policy & Regulation
Alligator Bioscience AB names Malin Carlsson PhD as COO
2 December 2019 -

Biotechnology company Alligator Bioscience (Nasdaq Stockholm:ATORX) revealed on Friday the addition of Malin Carlsson PhD as its chief operating officer.

Effective 1 January 2020, Dr Carlsson will have overall responsibility for the company's clinical projects, with emphasis on the development plans for the candidate drugs mitazalimab (ADC-1013) and ATOR-1015, both of which are planned to start phase II clinical studies in 2020.

Most recently, Dr Carlsson has served as vice president, head of Translational Medicine at Ferring Pharmaceuticals in Copenhagen.

Dr Carlsson has worked for many years in various senior roles at AstraZeneca, Nycomed, Takeda as well as Ferring.



Related Headlines